Investors bought shares of Rite Aid Corp. (NYSE:RAD) on weakness during trading on Monday. $28.88 million flowed into the stock on the tick-up and $16.32 million flowed out of the stock on the tick-down, for a money net flow of $12.56 million into the stock. Of all stocks tracked, Rite Aid Corp. had the 28th highest net in-flow for the day. Rite Aid Corp. traded down ($0.18) for the day and closed at $7.01

A number of equities analysts recently weighed in on RAD shares. Zacks Investment Research downgraded shares of Rite Aid Corp. from a “hold” rating to a “sell” rating in a research note on Monday, April 11th. Vetr downgraded shares of Rite Aid Corp. from a “strong-buy” rating to a “buy” rating and set a $9.03 target price for the company. in a research note on Wednesday, April 20th. Deutsche Bank AG downgraded shares of Rite Aid Corp. from a “buy” rating to a “hold” rating and lifted their target price for the stock from $8.09 to $9.00 in a research note on Friday, April 8th. Evercore ISI downgraded shares of Rite Aid Corp. from a “buy” rating to a “hold” rating in a research note on Wednesday, June 1st. Finally, JPMorgan Chase & Co. reissued a “hold” rating on shares of Rite Aid Corp. in a research note on Friday, June 17th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and six have assigned a buy rating to the company. Rite Aid Corp. has a consensus rating of “Hold” and an average target price of $9.34.

The firm has a market capitalization of $7.31 billion and a PE ratio of 51.93. The stock’s 50-day moving average price is $7.52 and its 200 day moving average price is $7.82.

Rite Aid Corp. (NYSE:RAD) last announced its quarterly earnings data on Thursday, June 16th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.05 by $0.04. The firm had revenue of $8.18 billion for the quarter. During the same period in the previous year, the business posted $0.02 earnings per share. The firm’s quarterly revenue was up 23.1% compared to the same quarter last year. On average, equities analysts anticipate that Rite Aid Corp. will post $0.16 EPS for the current fiscal year.

In other Rite Aid Corp. news, SVP Douglas E. Donley sold 34,106 shares of the stock in a transaction on Wednesday, June 15th. The shares were sold at an average price of $7.77, for a total transaction of $265,003.62. Following the completion of the sale, the senior vice president now owns 82,885 shares of the company’s stock, valued at approximately $644,016.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

A number of large investors have recently made changes to their positions in RAD. Morgan Stanley boosted its stake in shares of Rite Aid Corp. by 69.5% in the fourth quarter. Morgan Stanley now owns 11,706,349 shares of the company’s stock valued at $91,778,000 after buying an additional 4,797,918 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Rite Aid Corp. by 6.7% in the fourth quarter. Vanguard Group Inc. now owns 70,299,320 shares of the company’s stock valued at $551,146,000 after buying an additional 4,417,367 shares during the last quarter. Gabelli Funds LLC purchased a new stake in shares of Rite Aid Corp. during the fourth quarter valued at $17,353,000. State of New Jersey Common Pension Fund D purchased a new stake in shares of Rite Aid Corp. during the fourth quarter valued at $12,544,000. Finally, Cowen Group Inc. purchased a new stake in shares of Rite Aid Corp. during the fourth quarter valued at $12,493,000.

Rite Aid Corporation is a retail drugstore chain. The Company sells prescription drugs and a range of other merchandise, which are referred to as front-end products. The Company’s drugstores’ primary business is pharmacy services. It operates approximately 4,570 stores in 31 states across the country and in the District of Columbia.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.